Concordia Healthcare Corp. (NASDAQ:CXRX)’s share price fell 4.9% on Wednesday . The company traded as low as $19.57 and last traded at $20.02, with a volume of 155,870 shares. The stock had previously closed at $21.06.

A number of research firms have weighed in on CXRX. Canaccord Genuity reaffirmed a “buy” rating on shares of Concordia Healthcare Corp. in a research report on Saturday, April 23rd. TD Securities reaffirmed a “buy” rating and set a $45.00 price target (down previously from $48.00) on shares of Concordia Healthcare Corp. in a research report on Thursday, March 31st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $74.00 price target (down previously from $75.00) on shares of Concordia Healthcare Corp. in a research report on Tuesday, May 17th. Finally, Zacks Investment Research raised Concordia Healthcare Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $52.35.

The firm has a 50-day moving average of $25.21 and a 200-day moving average of $28.56. The stock’s market cap is $1.06 billion.

Concordia Healthcare Corp. (NASDAQ:CXRX) last released its quarterly earnings data on Friday, May 13th. The company reported $1.35 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.54 by $0.19. The firm earned $228.50 million during the quarter, compared to analysts’ expectations of $231 million. The firm’s quarterly revenue was up 570.1% on a year-over-year basis. On average, equities analysts forecast that Concordia Healthcare Corp. will post $6.17 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Friday, July 15th will be issued a dividend of $0.075 per share. The ex-dividend date is Wednesday, July 13th. This represents a $0.30 annualized dividend and a dividend yield of 1.43%.

Other hedge funds and institutional investors recently made changes to their positions in the company. Diamond Hill Capital Management Inc. boosted its position in shares of Concordia Healthcare Corp. by 294.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 850,645 shares of the company’s stock valued at $34,732,000 after buying an additional 634,880 shares during the last quarter. Morgan Stanley boosted its position in shares of Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock valued at $11,015,000 after buying an additional 53,305 shares during the last quarter. Thornburg Investment Management Inc. boosted its position in shares of Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock valued at $4,746,000 after buying an additional 37,847 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Concordia Healthcare Corp. during the fourth quarter valued at about $2,419,000. Finally, Swiss National Bank boosted its position in shares of Concordia Healthcare Corp. by 26.7% in the fourth quarter. Swiss National Bank now owns 49,810 shares of the company’s stock valued at $2,031,000 after buying an additional 10,510 shares during the last quarter.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.